Medical device firm Intact Vascular has closed enrollment in the tack optimised balloon angioplasty II (TOBA II) clinical trial of its Tack Endovascular system to treat patients with peripheral arterial disease (PAD).

The Tack Endovascular system technology is being developed to repair dissections/tears that occur in artery walls during standard or drug coated balloon (DCB) angioplasty.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective, multi-centre, two-arm, non-randomised TOBA II trial has enrolled a total of 210 patients at 33 sites in the US and Europe.

"The Tack system allows repair while leaving a minimal amount of foreign material in the artery, it reduces mechanical stress on the artery and preserves future treatment options."

The trial evaluated the the safety and efficacy of the Tack Endovascular system in combination with standard or DCB angioplasty using the BARD Lutonix in the arteries above the knee.

The superficial femoral artery (SFA) and the proximal segment of the popliteal artery have been targeted during the trial.

See Also:

Intact Vascular co-founder and chief medical officer Dr Peter Schneider said: “The Tack Endovascular system was conceived as a minimal metal approach to dissection repair, and that idea has become even more important with the advent of drug coated balloon angioplasty."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's primary effectiveness endpoint is Duplex derived patency at 12 months after treatment.

The Tack system allows repair while leaving a minimal amount of foreign material in the artery, it reduces mechanical stress on the artery and preserves future treatment options.

The system is being investigated further in TOBA II BTK trial which includes combination of the system with plain balloon angioplasty to target the arteries below the knee, and TOBA III trial which involves its combination with Medtronic's IN.PACT Admiral DCB in Europe.